Key Highlights

● Third-quarter sales reached about $13 billion, up 7% on a comparable basis.

● Adjusted Earnings Per Share rose to $1.42 from $1.30 a year earlier.

● Reported earnings per share fell to 53 cents because of legal settlements and amortization.

● Full-year adjusted earnings guidance was narrowed to $5.50 to $5.55 with the midpoint unchanged.

Abbott Laboratories (NYSE:ABT) closed its third quarter with a set of numbers that point in two directions at once. Sales reached about $13 billion, a rise of more than 14% as reported and 7% on the comparable basis the company prefers, while adjusted earnings per share climbed to $1.42 from $1.30 a year earlier. Yet reported earnings per share dropped to $0.53 from $0.94, a decline of more than 40%, because the quarter carried large settlement and amortization charges.

The results were released in the third week of October and filed with the Securities and Exchange Commission as an exhibit to a current report. Management narrowed its full-year adjusted earnings guidance to a range of $5.50 to $5.55, left the midpoint unchanged, and also gave a fourth-quarter range. It did not give guidance on a reported basis, saying that restructuring, impairments and currency swings are hard to estimate.

What did Abbott actually report for the quarter?

Net sales were $13.013 billion, compared with about 11.4 billion a year before. Growth was 14.5% as reported and 7% on a comparable basis, a measure that removes currency effects and certain compensation payments in the structural heart Business and that includes Exact Sciences in both periods so that the comparison is like for like.

Geography added another angle. Sales in the United States were about $5.5 billion, up 28% as reported because the cancer testing business is largely American, while international sales were about $7.5 billion, up just over 6% as reported. The mix has therefore shifted toward the home market since the deal closed.

For the first nine months of the year, sales were about $37 billion, up almost 12% as reported and just over 5% comparable. The slower nine-month comparable rate shows that the third quarter was one of the stronger stretches of the year for the underlying business, which is the context the company's chief executive had in mind when he described balanced growth across the portfolio.

Net earnings for the quarter were about $920 million, against roughly $1.64 billion a year earlier. Net interest expense climbed to nearly $300 million from a few dozen million, a direct result of the borrowing that accompanied the cancer diagnostics Acquisition earlier in the year.

Why did reported earnings fall while adjusted earnings rose for Abbott Laboratories?

The company reports two measures, and the distance between them was unusually wide. Specified items in the quarter totaled roughly $1.56 billion after tax, or $0.89 a share. The largest components were amortization of acquired intangible assets, at more than $800 million before tax, and about $670 million of legal settlements.

Those settlements resolved a lawsuit known as the Gill case and a group of claims tied to necrotizing enterocolitis, the intestinal condition at the center of litigation over preterm infant formula. Because the charges were booked as specified items, they are excluded from adjusted earnings, which is why the adjusted figure grew by 9% while the reported figure fell sharply.

Adjusted measures are common in large healthcare groups, but they are not defined by accounting rules, and readers are generally pointed to the reconciliation in the release. Over nine months, specified items totaled almost $4 billion, or $2.21 a share, and included about $400 million connected to a settlement with the Department of Justice.

How did the medical devices segment perform?

Medical devices produced sales of about $5.8 billion, up 7.8% on a comparable basis, and remained the largest of the four segments. Electrophysiology, which covers catheters and mapping systems used to treat irregular heart rhythms, was the standout with growth above 15%, and rhythm management, the pacemaker and defibrillator business, grew about 10%.

Diabetes care contributed about $2.2 billion, and sales of continuous glucose monitors rose roughly 7.7%. That pace is slower than the double-digit rates the Franchise posted in earlier years, which reflects a larger base and a more crowded field of competitors, but it still outgrew several other lines in the company.

The segment also supplied much of the product news. The company noted regulatory approval in the United States for an ablation catheter with dual energy capability and European certification for a left atrial appendage occluder, a device that closes off a small pouch in the heart where clots can form in patients with atrial fibrillation.

What changed in diagnostics after the Exact Sciences deal?

Diagnostics posted sales of about $3.3 billion, up more than 46% as reported but only 6.4% on a comparable basis. The difference is almost entirely the acquisition, which closed in late March and which brought in a cancer testing business that now reports inside the segment as cancer diagnostics.

That new unit generated nearly $1 billion of sales in the quarter, growing close to 14% on a comparable basis, with at-home colorectal screening and precision oncology tests named as drivers. The legacy core laboratory business grew about 5.5%, while rapid and molecular diagnostics, which has been shrinking since respiratory testing normalized, edged up less than 1%.

In April, when the company reported its first quarter, it had lowered its earnings guidance for the year to reflect dilution from the deal, which was priced at roughly $21 billion, and the shares fell on the day. The latest quarter therefore reads as an early test of whether the acquired business is growing at the pace management described when the deal was announced.

How are nutrition and established pharmaceuticals faring?

Nutrition sales were about $2.26 billion, a comparable gain of just under 5%. The pediatric formula line grew close to 9%, a pace that stood out within the segment. The company also pointed to a new formula made with whole milk that began shipping in the United States during the summer.

Established pharmaceuticals, which markets branded generics mainly in emerging markets, delivered the fastest segment growth at 8.4% on a comparable basis, with sales of about $1.6 billion. Key emerging markets within the group grew nearly 11%.

The legal settlements booked this quarter relate mainly to the infant formula litigation, so the segment's operating performance and its legal history are being reported on separate tracks. Readers who follow the formula litigation may note that settling a case on a given date does not necessarily end every related claim, and the filing includes language on pending matters.

What does the narrowed guidance mean in plain terms?

For the full year, adjusted earnings per share are now expected in a range of $5.50 to $5.55. The previous range was wider, and the midpoint was reaffirmed, so the change reduces the spread of outcomes without moving the center. Comparable sales growth is expected to be about 6% for the year.

Management also kept to its habit of stating that guidance excludes certain items, such as restructuring and Impairment charges. That convention explains why the company gives adjusted guidance only, and why readers wanting a full picture of expected reported earnings must add the specified items they judge likely.

The fourth-quarter range of $1.62 to $1.67 implies a seasonally strong close, since the nine-month adjusted figure was $3.88. Adding the fourth-quarter range to the nine-month result yields the full-year range, which is a simple arithmetic check that readers can do with the release in hand.

Narrowing a range late in the year is routine for large companies, and it often signals that management has good visibility into the remaining weeks. It also means that any shortfall against the fourth-quarter range would be easy to measure, which is why the next Quarterly Report will draw attention from people who follow the sector.

What new products did the company highlight?

The release lists five items. A dual glucose and ketone sensor, branded Libre Duo, received approval from the Food and Drug Administration in August, extending the company's wearable sensor line from glucose alone to a second marker that matters to people with diabetes who need to watch for ketone buildup.

In September, the company launched a blood-based screening test for colorectal cancer called SimpleScreen CRC, which fits with the Exact Sciences portfolio and widens the Options offered to patients who decline colonoscopy or stool-based kits. The ablation catheter approval, also in September, adds to a lineup in electrophysiology that is already growing faster than the segment average.

Product approvals matter in this industry because regulatory clearance is only the first step. Hospitals must add new catheters to procurement lists, payers must agree to cover tests, and clinicians must be trained, so the Revenue effect of an approval announced in one quarter is usually spread across many later periods.

The launch of the whole-milk formula in the nutrition business and the European certification of the appendage occluder complete the list. None of these items is quantified in the release, so their contribution to revenue will only become visible over several quarters as adoption builds and reimbursement settles.

How does the Dividend record fit into the picture?

The board declared a quarterly dividend of $0.63 a share, payable in mid-November. The company noted that this is its 400 eleventh consecutive quarterly dividend, and that it has raised the payout for 54 consecutive years.

A long dividend history places the company among the groups often discussed alongside other large dividend-focused names in the Healthcare Stocks category, though the board sets each payout individually and the release makes no promise about later declarations. The quarter's heavy charges did not change the declared amount.

Dividend decisions are made from cash generation and board judgment rather than from reported earnings alone, which is one reason adjusted measures and Cash Flow are quoted more often than the reported earnings figure when the payout is discussed. The filing contains the full Cash Flow Statement for readers who wish to compare.

How did the market and the index context look?

The stock is a member of the S&P 500 and ranks among the larger healthcare constituents, so its quarterly moves can register in sector funds that track the benchmark. Coverage of the release has centered on the gap between the two earnings measures, the settlements and the larger Debt load.

Earlier reports from the company have shown how sensitive sentiment can be to a single segment. In the prior year's third quarter, weakness in diagnostics and nutrition drew attention even though devices beat expectations, and this year the mix is better balanced, with every segment growing on a comparable basis.

The company's weight in the benchmark also means that its guidance changes feed into sector-level earnings aggregates. A narrowing that leaves the midpoint unchanged has little effect on those aggregates, whereas a cut or raise would move them, which is one reason the market treats the midpoint as the headline.

Share price moves around earnings reflect many inputs, including positioning and the broader market, and a single day's change says little about longer-run trends.

What are the main open questions for the coming quarters?

The first is integration. The cancer diagnostics unit is now a meaningful share of segment sales, and the company has said it expects the acquisition to add roughly $3 billion of sales in the first year of ownership. Whether growth stays near the rate reported this quarter will be visible in the next two reports.

The second is the pace of glucose monitoring growth, where competition and pricing remain active topics, and where the new dual sensor is the company's main new entry. The third is the legal calendar: with two sets of claims resolved this quarter, the question is how many related matters remain and how they are reserved.

A fourth item is the balance sheet. Net interest expense has risen substantially, and debt reduction is likely to feature in management commentary through the next year. The timing of any debt reduction depends on cash generation and on any further business development.

How does this quarter compare with the first half of the year?

The year began with a guidance cut tied to the acquisition and a diabetes care line that came in below expectations in the first quarter. Comparable growth of 7% in the third quarter is above the full-year pace of about 6% that management now projects.

Because the full-year guide of about 6% sits below the latest quarterly rate, the arithmetic implies a somewhat softer fourth quarter on a comparable basis, or a conservative stance by management. Either reading is consistent with a company that prefers to leave room, and the fourth-quarter earnings range reflects that cautious stance.

Readers comparing quarters should note that the comparable growth measure now includes Exact Sciences in both periods, so the first half of the year, reported before that adjustment was fully available, is not perfectly comparable to the third quarter. The company's supplemental tables give restated figures.